2023
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, Philley J, Desruisseaux M, Keller M, Hochman J, Pirofski L, Ortigoza M, Hochman J, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Ortigoza M, Pirofski L, Yoon H, Sturm-Reganato C, Cobb G, Andela R, Darwish Y, Taveras M, Xin P, LaFleur J, Cleare L, Goldfeld K, Li Y, Ortigoza M, O'Keeffe M, Cobb G, Sturm-Reganato C, Rahman F, Ajayi A, Rodriguez S, Iturrate E, Gallagher J, Thomas O, Ramos D, Fong C, Pirofski L, Yoon H, Keller M, Asencio A, Eke I, Castro J, Shan J, Chalco A, LaFleur J, Cleare L, Desruisseaux M, Cortezzo G, Rocco E, Ndunge O, Parmelee C, Solomon G, Cahil S, Jayaweera D, Lee C, Ransford D, Dasmany D, Corona A, Moreno K, Martinez G, Otero C, McPherson D, Ostrosky-Zeichner L, Patel B, Nigo M, Huebinger R, Dronavalli G, Grimes C, Umana V, Hernandez M, Nielsen L, Stutz T, Mammadova M, Dentino A, Heath T, Martin J, Bello F, Hinojosa E, Philley J, Devine M, Hibbard R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases 2023, 11: ofad686. PMID: 38269049, PMCID: PMC10807994, DOI: 10.1093/ofid/ofad686.Peer-Reviewed Original ResearchPost-acute sequelaePROMIS scoresCOVID-19 convalescent plasma (CCP) therapySARS-CoV-2 infection symptomsSARS-CoV-2 infectionAcute COVID-19Convalescent plasma therapyGlobal health assessmentPhysical health scoresCOVID-19 hospitalizationCOVID-19 trialsSelf-reported symptomsRespective reference groupsRace/ethnicityPASC symptomsRandomization armAcute infectionAcute treatmentPlasma therapyGeneral symptomsSymptom SurveyLong-term effectsHealth scoresOverall healthDisease severityEffects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria
Ndunge O, Shikani H, Dai M, Freeman B, Desruisseaux M. Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria. Journal Of Neurochemistry 2023, 167: 441-460. PMID: 37814468, PMCID: PMC10596299, DOI: 10.1111/jnc.15972.Peer-Reviewed Original ResearchConceptsNeural cell injuryCerebral malariaExperimental CMCell injuryUninfected micePHF-1Cell activationNeurodegenerative diseasesAbnormal regulationExperimental modelAnti-tau immunotherapyTau-targeting therapiesExperimental cerebral malariaGlial cell activationPlasmodium berghei ANKAPlasmodium berghei NK65Abnormal tau phosphorylationSubsequent neurocognitive impairmentSignificant memory impairmentNeural cell damageMicrovascular congestionPbA infectionInflammatory markersBerghei ANKANeurological deficitsIntegrated Care Models: HIV and Substance Use
Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 20: 286-295. PMID: 37698755, PMCID: PMC11034717, DOI: 10.1007/s11904-023-00667-9.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersSubstance useIntegrated careRecent HIV outbreaksHIV viral suppressionMultidisciplinary care teamHIV virologic suppressionOpioid use disorderRisk of HIVHarm reduction programsSubstance use treatmentEvidence-based strategiesVirologic suppressionViral suppressionHIV outbreakCare teamProvider trainingHIVOnward transmissionHealth outcomesCare servicesClinic leadershipCare integrationMedical literatureBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquity
2022
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Inclusion, Diversity, Access, and Equity (IDA&E) Roadmap: Infectious Diseases Society of America’s Commitment to the Future
Desruisseaux MS, Tan TQ. Inclusion, Diversity, Access, and Equity (IDA&E) Roadmap: Infectious Diseases Society of America’s Commitment to the Future. The Journal Of Infectious Diseases 2020, 222: s523-s527. PMID: 32926738, DOI: 10.1093/infdis/jiaa153.Commentaries, Editorials and Letters
2019
Captain Herbert B. Tanowitz, M.D., F.I.D.S.A., F.A.C.P., F.R.S.T.M.H., 1941–2018
Desruisseaux M, Engman D. Captain Herbert B. Tanowitz, M.D., F.I.D.S.A., F.A.C.P., F.R.S.T.M.H., 1941–2018. American Journal Of Pathology 2019, 189: 2-3. DOI: 10.1016/j.ajpath.2018.10.003.Commentaries, Editorials and Letters
2018
Endothelins in inflammatory neurological diseases
D'Orléans-Juste P, Akide Ndunge O, Desbiens L, Tanowitz HB, Desruisseaux MS. Endothelins in inflammatory neurological diseases. Pharmacology & Therapeutics 2018, 194: 145-160. PMID: 30291906, PMCID: PMC6348026, DOI: 10.1016/j.pharmthera.2018.10.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCentral nervous systemNeuroinflammatory processesCentral nervous system vasculitisNon-infectious inflammatory processesBlood-brain barrier levelEndothelin-1 antagonistsSynthesis of endothelinInflammatory neurological diseasesMediator/modulatorProgression of neurodegenerationPotent vasoactive compoundsNeuroinflammatory diseasesEndothelin pathwayEndothelin-1Inflammatory processClinical trialsVasoactive compoundsCardiovascular propertiesNervous systemAmino acid peptideNeurological diseasesEndothelial integrityEndothelinAlzheimer's diseaseNeurodegenerative disordersTrypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2
Colas RA, Ashton AW, Mukherjee S, Dalli J, Akide-Ndunge OB, Huang H, Desruisseaux MS, Guan F, Jelicks LA, dos Santos F, Nagajyothi J, Zingman MA, Reyes J, Weiss LM, Serhan CN, Tanowitz HB. Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. Infection And Immunity 2018, 86: 10.1128/iai.00688-17. PMID: 29358332, PMCID: PMC5865043, DOI: 10.1128/iai.00688-17.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayResolvin D1Chagas diseaseMediators of inflammationCD-1 miceRvD1 levelsChronic cardiomyopathyAcute myocarditisMyocardial inflammationProinflammatory eicosanoidsProresolving mediatorsChronic phasePathological featuresPlasma levelsLifelong infectionLipid mediatorsResolvin D5Host responseHuman infectionsBacterial infectionsRvD1InflammationInfectionImmunosorbent assayElevated levels
2016
Endothelin-1 Treatment Induces an Experimental Cerebral Malaria–Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei NK65
Martins YC, Freeman BD, Ndunge O, Weiss LM, Tanowitz HB, Desruisseaux MS. Endothelin-1 Treatment Induces an Experimental Cerebral Malaria–Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei NK65. American Journal Of Pathology 2016, 186: 2957-2969. PMID: 27640146, PMCID: PMC5222963, DOI: 10.1016/j.ajpath.2016.07.020.Peer-Reviewed Original ResearchConceptsExperimental cerebral malariaEndothelin-1ET-1 treatmentC57BL/6 miceBerghei NK65Pathogenesis of ECMBlood-brain barrier leakagePlasmodium berghei ANKA infectionBlood-brain barrier permeabilitySevere malarial diseasePlasmodium berghei ANKABerghei ANKA infectionP. berghei NK65Plasmodium berghei NK65Functional capillary densityEndothelin-1 treatmentCerebral malariaMicrovascular alterationsANKA infectionBerghei ANKARed blood cellsVascular dysfunctionCerebral microvasculatureNeurological signsBarrier leakageEndothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria
Freeman BD, Martins YC, Akide-Ndunge OB, Bruno FP, Wang H, Tanowitz HB, Spray DC, Desruisseaux MS. Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria. PLOS Pathogens 2016, 12: e1005477. PMID: 27031954, PMCID: PMC4816336, DOI: 10.1371/journal.ppat.1005477.Peer-Reviewed Original ResearchConceptsExperimental cerebral malariaCerebral malariaEndothelin-1Cognitive impairmentExperimental cerebral malaria modelBlood-brain barrier disruptionLong-term cognitive impairmentCerebral malaria modelEndothelin-1 administrationLife-threatening encephalopathyBerghei ANKA infectionPlasmodium falciparum infectionCerebral malaria pathogenesisBrain microvascular dysfunctionMicrovascular congestionCerebral vasoconstrictionAdjunctive therapyANKA infectionBerghei ANKAMicrovascular dysfunctionFalciparum infectionImproved survivalEndothelial activationBarrier disruptionReceptor antagonistChapter 14 Trypanosoma cruzi and Chagas Disease: Innate Immunity, ROS, and Cardiovascular System
Tanowitz H, Wen J, Machado F, Desruisseaux M, Robello C, Garg N. Chapter 14 Trypanosoma cruzi and Chagas Disease: Innate Immunity, ROS, and Cardiovascular System. 2016, 183-193. DOI: 10.1016/b978-0-12-801078-5.00014-5.ChaptersChagas diseaseThromboxane A2Innate immunityAnti-inflammatory factorsContribution of cytokinesTrypanosoma cruziSignificant morbidityVasoconstrictive actionEndothelin-1Nonendemic areasEndemic areasEicosanoid pathwayCardiovascular systemDiseaseNatural transmissionImmunityOxygen speciesCruziMorbidityChemokinesA2CytokinesPathogenesisLipoxinsMortality
2015
The Brain Microvasculature in Cerebral Malaria
Dorovini-Zis K, Stins M, Desruisseaux M, Martins Y, van der Heyde H. The Brain Microvasculature in Cerebral Malaria. 2015, 68-117. DOI: 10.1201/b19299-5.ChaptersThe Brain Microvasculature in Cerebral Malaria
Dorovini-Zis K, Stins M, Desruisseaux M, Martins Y, van der Heyde H. The Brain Microvasculature in Cerebral Malaria. 2015, 68-117. DOI: 10.1201/b19299-4.Peer-Reviewed Original ResearchType of malariaInfection of erythrocytesFemale Anopheles mosquitoesCerebral malariaPeriod of feverGenus PlasmodiumClinical typesMalariaMolecular genetic studiesBrain microvasculatureEarly nineteenth centuryNineteenth centuryHuman bloodAreas of AfricaGenetic studiesPlasmodiumMorbidityFeverInfectionMicrovasculatureBloodMortality
2014
Endothelin-1 and its role in the pathogenesis of infectious diseases
Freeman BD, Machado FS, Tanowitz HB, Desruisseaux MS. Endothelin-1 and its role in the pathogenesis of infectious diseases. Life Sciences 2014, 118: 110-119. PMID: 24780317, PMCID: PMC4538933, DOI: 10.1016/j.lfs.2014.04.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEndothelin-1Isoforms of endothelinRole of endothelinRickettsia conorii infectionPathogenesis of sepsisPro-inflammatory cytokinesVascular smooth muscle cellsLeukocyte adhesion moleculesSmooth muscle cellsSevere malariaVascular dysfunctionBacterial pneumoniaInflammatory mediatorsVascular tonePotent vasoconstrictorImmunomodulatory propertiesInfectious processAlveolar macrophagesPlatelet aggregationInfectious diseasesMuscle cellsEndothelinAdhesion moleculesPathogenesisChagas disease
2013
Endothelin-1 treatment induces experimental cerebral malaria during Plasmodium berghei NK65 infection
Martins Y, Tanowitz H, Weiss L, Desruisseaux M. Endothelin-1 treatment induces experimental cerebral malaria during Plasmodium berghei NK65 infection. Life Sciences 2013, 93: e27. DOI: 10.1016/j.lfs.2013.12.107.Peer-Reviewed Original ResearchThe role of endothelin-1 in the vascular pathobiology of cerebral malaria
Freeman B, Dai M, Desruisseaux M. The role of endothelin-1 in the vascular pathobiology of cerebral malaria. Life Sciences 2013, 93: e7. DOI: 10.1016/j.lfs.2013.12.045.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAlterations in Glucose Homeostasis in a Murine Model of Chagas Disease
Nagajyothi F, Kuliawat R, Kusminski CM, Machado FS, Desruisseaux MS, Zhao D, Schwartz GJ, Huang H, Albanese C, Lisanti MP, Singh R, Li F, Weiss LM, Factor SM, Pessin JE, Scherer PE, Tanowitz HB. Alterations in Glucose Homeostasis in a Murine Model of Chagas Disease. American Journal Of Pathology 2013, 182: 886-894. PMID: 23321322, PMCID: PMC3586686, DOI: 10.1016/j.ajpath.2012.11.027.Peer-Reviewed Original ResearchConceptsPancreatic β-cellsChagas diseaseΒ-cellsGlucose-6-phosphatase mRNAChronic phaseInsulin levelsCruzi infectionGlucose homeostasisPlasma membraneInsulin granulesΒ-cell dysfunctionTrypanosoma cruziHost glucose homeostasisT. cruzi infectionElevated glucagon levelsΑ-cell functionAdrenergic receptor agonistDiminished insulin responsePancreatic islet architectureReduced insulinMice resultsAcute infectionCardiac dysfunctionGlucagon levelsPancreatic inflammation
2012
Imaging of Small-Animal Models of Infectious Diseases
Jelicks LA, Lisanti MP, Machado FS, Weiss LM, Tanowitz HB, Desruisseaux MS. Imaging of Small-Animal Models of Infectious Diseases. American Journal Of Pathology 2012, 182: 296-304. PMID: 23201133, PMCID: PMC3969504, DOI: 10.1016/j.ajpath.2012.09.026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements